Transdermal Patch of an Antihypertensive Drug
Transdermal Patch
Versandkostenfrei!
Versandfertig in 6-10 Tagen
33,99 €
inkl. MwSt.
PAYBACK Punkte
17 °P sammeln!
The scenario of the research was to develop a polymer matrix diffusion controlled transdermal drug delivery system containing drug Telmisartan with different ratio of hydrophilic (HPMC) and lipophilic (EC, Eudragit RS 100) polymeric system by solvent casting technique on aluminum foil by using 30% w/v Dibutyl Phthalate of the polymeric weight, incorporated as plasticizer and 20% w/v, 30% w/v Dimethyl Sulfoxide( polymeric weight) was used to be permeation enhancer for transdermal drug release. Total Nine formulation developed by using same drug and different polymeric ratio. All transdermal pat...
The scenario of the research was to develop a polymer matrix diffusion controlled transdermal drug delivery system containing drug Telmisartan with different ratio of hydrophilic (HPMC) and lipophilic (EC, Eudragit RS 100) polymeric system by solvent casting technique on aluminum foil by using 30% w/v Dibutyl Phthalate of the polymeric weight, incorporated as plasticizer and 20% w/v, 30% w/v Dimethyl Sulfoxide( polymeric weight) was used to be permeation enhancer for transdermal drug release. Total Nine formulation developed by using same drug and different polymeric ratio. All transdermal patches were physicochemical evaluated with thickness, weight variation, % moisture uptake, % moisture loss, folding endurance, flatness, drug content and % drug release. . The invitro permeation study performed by diffusion cells. The maximum invitro % drug release was observed up to 48 hrs with formulation F8 containing HPMC: EC: Eudragit RS 100 in (5:0:1) ratio.
Andere Kunden interessierten sich für
